1256393-27-7 Usage
General Description
Ledipasvir intermediate is a chemical compound that is used in the synthesis of ledipasvir, a medication used to treat chronic hepatitis C virus (HCV) infection. The intermediate plays a crucial role in the production of ledipasvir by serving as a building block in the chemical reaction process. It is specifically designed to help create the final molecular structure of ledipasvir, which is an inhibitor of the HCV NS5A protein. The intermediate undergoes various chemical transformations and purification steps to ultimately form ledipasvir, which has been proven to be highly effective in the treatment of HCV infection when used in combination with other antiviral medications. Overall, ledipasvir intermediate is a vital component in the pharmaceutical manufacturing process of ledipasvir, ultimately contributing to the production of a medication that has significantly improved the treatment of chronic HCV infection.
Check Digit Verification of cas no
The CAS Registry Mumber 1256393-27-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,3,9 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1256393-27:
(9*1)+(8*2)+(7*5)+(6*6)+(5*3)+(4*9)+(3*3)+(2*2)+(1*7)=167
167 % 10 = 7
So 1256393-27-7 is a valid CAS Registry Number.
1256393-27-7Relevant articles and documents
METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR
-
, (2018/04/14)
Methods of preparing Ledipasvir and derivatives thereof, and intermediate compounds used in the preparation of Ledipasvir are provided. Specifically, a method for preparing the compounds of formula 1 and a series of preparation methods of preparing Ledipasvir are provided. The methods described herein are simple and efficient, and have better application prospects.
PROCESS FOR PREPARATION OF LEDIPASVIR
-
Page/Page column 24; 25, (2017/09/15)
The present invention relates to a process for the preparation of ledipasvir a compound of formula I, which is useful as an antiviral agent. The present invention also provides ledipasvir phosphate.
METHODS FOR TREATING HCV
-
, (2013/03/28)
This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.